JPMorgan Chase & Co’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $2.07B | Buy |
|
|||||
|
2025
Q2 | $672M | Sell |
|
|||||
|
2025
Q1 | $599M | Sell |
|
|||||
|
2024
Q4 | $529M | Buy |
|
|||||
|
2024
Q3 | $595M | Buy |
|
|||||
|
2024
Q2 | $431M | Buy |
|
|||||
|
2024
Q1 | $261M | Sell |
|
|||||
|
2023
Q4 | $577M | Sell |
|
|||||
|
2023
Q3 | $547M | Sell |
|
|||||
|
2023
Q2 | $595M | Buy |
|
|||||
|
2023
Q1 | $620M | Sell |
|
|||||
|
2022
Q4 | $743M | Buy |
|
|||||
|
2022
Q3 | $509M | Buy |
|
|||||
|
2022
Q2 | $333M | Sell |
|
|||||
|
2022
Q1 | $477M | Sell |
|
|||||
|
2021
Q4 | $504M | Buy |
|
|||||
|
2021
Q3 | $462M | Sell |
|
|||||
|
2021
Q2 | $439M | Buy |
|
|||||
|
2021
Q1 | $308M | Sell |
|
|||||
|
2020
Q4 | $300M | Buy |
|
|||||
|
2020
Q3 | $330M | Buy |
|
|||||
|
2020
Q2 | $329M | Buy |
|
|||||
|
2020
Q1 | $91.7M | Buy |
|
|||||
|
2019
Q4 | $68.2M | Sell |
|
|||||
|
2019
Q3 | $52.1M | Sell |
|
|||||
|
2019
Q2 | $47.3M | Buy |
|
|||||
|
2019
Q1 | $60.9M | Buy |
|
|||||
|
2018
Q4 | $32.5M | Sell |
|
|||||
|
2018
Q3 | $86.3M | Buy |
|
|||||
|
2018
Q2 | $62.3M | Buy |
|
|||||
|
2018
Q1 | $6.64M | Buy |
|
|||||
|
2017
Q4 | $1.71M | Sell |
|
|||||
|
2017
Q3 | $1.78M | Sell |
|
|||||
|
2017
Q2 | $4.41M | Sell |
|
|||||
|
2017
Q1 | $3.23M | Buy |
|
|||||
|
2016
Q4 | $2.11M | Buy |
|
|||||
|
2016
Q3 | $1.8M | Sell |
|
|||||
|
2016
Q2 | $1.72M | Sell |
|
|||||
|
2016
Q1 | $2.4M | Buy |
|
|||||
|
2015
Q4 | $3.55M | Sell |
|
|||||
|
2015
Q3 | $12.4M | Sell |
|
|||||
|
2015
Q2 | $35.1M | Sell |
|
|||||
|
2015
Q1 | $55M | Sell |
|
|||||
|
2014
Q4 | $62.9M | Buy |
|
|||||
|
2014
Q3 | $39.4M | Sell |
|
|||||
|
2014
Q2 | $32.2M | Buy |
|
|||||
|
2014
Q1 | $27.6M | Buy |
|
|||||
|
2013
Q4 | $18.4M | Sell |
|
|||||
|
2013
Q3 | $19.2M | Buy |
|
|||||
|
2013
Q2 | $8.36M | Buy |
|